At least 1,200 U.S. plaintiffs have filed Xarelto lawsuits after allegedly suffering serious complications due to its use. Yet the burgeoning litigation shows no signs of slowing the drug’s sales, which were up more than 43% during the second quarter of this year.
According to an investor report issued by Bayer last week, all of the pending Xarelto cases seek compensatory and punitive damages for personal injuries allegedly related to the use of the medication, including cerebral, gastrointestinal or other bleeding and death. The company expects that more cases will eventually be filed. At lease six Xarelto class actions that put forth similar allegations are also pending in Canadian courts.
If these lawsuits are impacting sales at all, the effect is negligible. In the second quarter of 2015, the drug generated $600 million in Revenue for Bayer.
“We are marketing Xarelto in 60-70 countries at the moment so the introduction has been very successful,” Bayer’s CEO told CNBC late last month. “In the United States at the moment, Xarelto has more market share than all of the other oral anti-coagulants combined of our competitors,”
Xarelto is a new generation blood thinner that has been available in the U.S. since 2011. Like any anticoagulant, some patients treated with Xarelto may experience serious internal hemorrhaging. However, no reversal agent has yet been approved for Xarelto bleeding. By contrast, hemorrhaging caused by a much older blood-thinning medication called warfarin can be stopped by the administration of vitamin K.
Plaintiffs have accused Bayer of wrongly marketing Xarelto as a superior alternative to warfarin, despite the absence of an antidote for its potentially life-threatening bleeding side effects. Plaintiffs also take issue with marketing claims that characterized the medication as easier to use than warfarin because it does not require regular blood monitoring to ensure patients are receiving the appropriate dose. Xarelto lawsuits charge that a regular testing protocol would actually benefit patients using the drug.
On the federal level, more than 500 Xarelto injury claims have been filed in a multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, where trials could begin next August. Additional cases are pending in various state courts, including more than 200 that have been filed in mass tort litigation underway in the Philadelphia Court of Common Pleas.
Bernstein Liebhard LLP is representing alleged victims of Xarelto bleeding, and our attorneys continue to offer free legal reviews to alleged victims of this medication. To learn if you qualify to file a Xarelto lawsuit, please give our office a call at .